Form 10-Q Krystal Biotech, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Krystal Biotech (KRYS) PT Raised to $206 at Citi
November 4, 2024 4:42 PM ESTCiti analyst Carly Kenselaar raised the price target on Krystal Biotech (NASDAQ: KRYS) to $206.00 (from $204.00) while maintaining a Neutral rating.
The analyst comments "Though Vyjuvek sales of $83.8M were in-line vs. Citi/consensus of $82.3M/$83.4M, key risks associated with our... More
